CClinicalTrials.gg
CompletedNCT07705516Updated Jul 15, 2026

Interfascial Abdominal Wall Block for Gynecological Laparoskopy: A Randomized Clinical Trial

An interventional study of Bilateral QLB and RSB and Bilateral QLB alone in Postoperative Pain and Pelvic Pain, sponsored by Medical and Diagnostic Center "MEDION" LLC. Completed at 1 site in Ukraine. Open to female participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Medical and Diagnostic Center "MEDION" LLC · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Jan 2025, registered Jul 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
Female
01

Study summary

The purpose of this study is to evaluate the clinical efficacy of combining ultrasound-guided bilateral rectus sheath blocks (RSB) and quadratus lumborum blocks (QLB) compared to using a quadratus lumborum block alone for postoperative analgesia in patients undergoing laparoscopic gynecological surgeries.

The primary objective is to assess movement-evoked pain scores in the early postoperative period. Secondary objectives include the evaluation of postoperative opioid consumption, intraoperative hemodynamic stability, and the overall incidence of side effects. Investigators hypothesize that the combined interfacial abdominal wall block technique will provide superior pain relief and reduce opioid requirements during recovery.

02

Conditions studied

  • Postoperative Pain
  • Pelvic Pain

Keywords

  • Quadratus Lumborum Block
  • Rectus Sheath Block
  • Laparoscopy
  • Gynecologic Surgical Procedures
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 50 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

This is the only study on the registry with Medical and Diagnostic Center "MEDION" LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Scheduled for elective gynecological video-laparoscopic surgery.
  • ASA physical status І-ІІ.
  • Age between 18 and 65 years.
  • Patient's informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Known allergy or contraindications to local anesthetics.
  • Infection at the potential needle insertion sites.
  • Coagulopathy or ongoing anticoagulant therapy.
  • Conversion to open laparotomy during surgery.
  • Severe cognitive impairment or psychiatric disorders.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    QLB + RSB Group

    Combined regional anesthesia. Bilateral QL block technique. Bilateral RSB technique. Ultrasound-guided injections. Standard local anesthetics. Postoperative pain management.

    Procedure: Bilateral QLB and RSB

  • Active comparator
    QLB Group

    Isolated regional anesthesia. Bilateral QLB technique. No rectus sheath block. Ultrasound-guided injections. Standard local anesthetics. Postoperative pain management.

    Procedure: Bilateral QLB alone

Interventions

  • ProcedureBilateral QLB and RSB

    Preoperative regional anesthesia. Bilateral QL block combined with bilateral RS block. Ultrasound-guided technique. Using local anesthetics.

  • ProcedureBilateral QLB alone

    Preoperative regional anesthesia. Isolated bilateral QL block. No rectus sheath block. Ultrasound-guided technique. Using local anesthetics.

06

What researchers measure

Primary outcomes

  1. Postoperative pain intensity

    Visual Analog Scale (VAS) score. Scale from 0 to 10. 0 means no pain. 10 means worst pain. Lower scores sindicate less pain.

    Time frame: At 2, 4, 6, 12, and 24 hours postoperative assessment

Secondary outcomes

  1. Total opioid consumption. Postoperative period. Measured in milligrams.

    Total dose of opioid analgesics. Administered within 24 hours. Measured in milligrams (mg). Lower doses indicate better opioid-sparing effect.

    Time frame: Within 24 hours after surgery.

07

Study locations

1 site
  • Medical and Diagnostic Center "MEDION" LLC
    Poltava, Poltava Oblast 36039, Ukraine
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect patient privacy. All collected clinical data will remain confidential within the medical center. The study protocol and statistical methods may be available upon direct request.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07705516
Lead sponsor
Medical and Diagnostic Center "MEDION" LLC
Responsible party
Slipukha Denys (Staff Anesthesiologist, Medical and Diagnostic Center "MEDION" LLC) — Principal investigator
First posted
Jul 15, 2026
Start date
Jan 7, 2025
Primary completion
Dec 27, 2025
Completion
Dec 28, 2025
Last update
Jul 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion